ClinicalTrials.Veeva
Menu

Find clinical trials for Lung Cancer in Montréal, QC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Non-Small-Cell Lung Carcinoma
Cancer
Carcinoma
Small Cell Lung Carcinoma
Squamous Cell Carcinoma of Head and Neck
Triple Negative Breast Cancer
Colorectal Cancer

Lung Cancer trials near Montréal, QC, CAN:

Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer (ARC-7)

and domvanalimab in combination with zimberelimab and etrumadenant (AB928) in front-line, PD-L1 positive, metastatic non-small cell lung cancer...

Active, not recruiting
Squamous Non Small Cell Lung Cancer
Nonsquamous Non Small Cell Lung Cancer
Drug: Etrumadenant
Drug: Zimberelimab

Phase 2

Arcus Biosciences
Arcus Biosciences

Montreal, Canada and 47 other locations

Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer (KontRASt-02)

to docetaxel in participants with advanced non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation who have been previous...

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: JDQ443
Drug: docetaxel

Phase 3

Novartis
Novartis

Montreal, Quebec, Canada and 51 other locations

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung...

Enrolling
Metastatic Non Small Cell Lung Cancer
Biological: LN-145

Phase 2

Iovance Biotherapeutics

Montréal, Canada and 63 other locations

Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)

with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with or without actionable genomic alterations....

Active, not recruiting
Non-small Cell Lung Cancer
Drug: Docetaxel
Drug: DS-1062a

Phase 3

Daiichi Sankyo
Daiichi Sankyo

Montréal, Quebec, Canada and 209 other locations

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer (NeoCOAST-2)

resectable, early-stage non-small cell lung cancer....

Enrolling
Non-small Cell Lung Cancer
Drug: Cisplatin
Drug: Rilvegostomig

Phase 2

AstraZeneca
AstraZeneca

Montreal, Quebec, Canada and 96 other locations

Testing Experimental Anti-cancer Drug SLC-391 with an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers

combination with pembrolizumab in participants with non-small cell lung cancer (NSCLC).Each treatment cycle lasts 21 days. Particip...

Enrolling
Lung Cancer Metastatic
Lung Cancer Stage IV
Biological: pembrolizumab
Drug: SLC-391

Phase 1, Phase 2

SignalChem Lifesciences

Montréal, Quebec, Canada and 12 other locations

Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC)

This is a Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as...

Active, not recruiting
Small Cell Lung Cancer
Drug: Durvalumab
Other: Placebo

Phase 3

AstraZeneca
AstraZeneca

Montreal, Quebec, Canada and 182 other locations

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the ...

Enrolling
Non-small Cell Lung Cancer
Drug: Nab-paclitaxel
Drug: Pembrolizumab

Phase 3

AstraZeneca
AstraZeneca

Montréal, Quebec, Canada and 288 other locations

A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer (Krascendo 1)

KRAS G12C inhibitors (sotorasib or adagrasib) in participants with KRAS G12C-positive (KRAS G12C +) advanced or metastatic non-small cell lung...

Enrolling
KRAS G12C Lung Cancer
Non-Small Cell Lung Cancer
Drug: Sotorasib
Drug: Divarasib

Phase 3

Roche
Roche

Montreal, Quebec, Canada and 249 other locations

A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer (AEGEAN)

This is a Phase III, randomized, double-blind, placebo-controlled, multi-center international study assessing the activity of durvalumab and chemothe...

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: Durvalumab
Procedure: Surgery

Phase 3

AstraZeneca
AstraZeneca

Montreal, Quebec, Canada and 230 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2025 Veeva Systems